欢迎访问《现代生物医学进展》编辑部！

目的：探讨沙格列汀联合二甲双胍对2 型糖尿病的疗效与安全性。方法：选取200 例2 型糖尿病患者，按随机数字表法分为两组，沙格列汀组(102 例)口服沙格列汀联合二甲双胍治疗，阿卡波糖组(98 例)口服阿卡波糖联合二甲双胍治疗。通过观察并记录治疗前后糖代谢情况与体重指数水平，SF-36 量表各项评分，治疗期间不良反应情况，评价沙格列汀联合二甲双胍对2 型糖尿病的疗效与安全性。结果：治疗后，两组HbA1c，BMI，FBG，2 hPBG水平均明显下降(P<0.05)，且沙格列汀组患者HbA1c，BMI，FBG， 2 hPBG 水平明显低于阿卡波糖组(P<0.05)；治疗后3 个月两组患者SF-36 表各项评分均明显提高(P<0.05)，但两组间差异没有统计学意义(P>0.05)；随访期间，两组不良反应率相比，差异没有统计学意义(P>0.05)。结论：沙格列汀联合二甲双胍可以明显控制患者血糖水平，减轻患者体重，提高患者生活质量，用药安全性好，值得临床推广使用。

英文摘要:

Objective:To investigate the efficacy and safety of saxagliptin combined with metformin in the treatment of 2 type diabetes.Methods:200 patients who had 2 type diabetes were selected and divided into two groups randomly. The patients in saxagliptin group (102 cases) were given saxagliptin combined with metformin, and the patients in acarbose group (98 cases) were given saxagliptin combined with metformin. The efficacy and safety of saxagliptin combined with metformin in the treatment of 2 type diabetes was evaluated by the detection of the indexes of glucose metabolism and body weight, SF-36 scores before and after treatment and adverse reactions during therapy.Results:After treatment, the HbA1c, BMI, FBG, 2hPBG level of two group were decreased (P<0.05), and the HbA1c, BMI, FBG, 2hPBG level of the saxagliptin group were lower than that of the acarbose group (P<0.05). After treatment, the SF-36 scores of two groups were increased (P<0.05), but there were no statistical significance on SF-36 scores between two groups (P>0.05). During treatment, there were no statistical significance on the incidence of adverse reactions between two groups (P>0.05).Conclusion:Saxagliptin combined with metformin can significantly control the blood glucose levels and improve the quality of life of patients with good safety, worthy of clinical application.

View Full Text View/Add Comment Download reader